Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

ZBIO vs LQDA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

LQDA Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 7–3 Matrix Metrics)

LQDA Overall Winner 6-Pillar Tally: ZBIO 1 – 5 LQDA Matrix Metrics: ZBIO 3 – 7 LQDA

As of Nov 16, 2026, Liquidia Corporation (LQDA) is the stronger overall head-to-head candidate over Zenas BioPharma, Inc. (ZBIO) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ZBIO carries a Unified Composite Score of 49.4/100 (HOLD) at $27.93 (N/M Forward P/E, -2747.5% operating margin), whereas LQDA carries 25.6/100 (SELL) at $56.37 (16.4x Forward P/E, 47.1% operating margin).

  • Composite vs. Pillar Nuance: While ZBIO currently prints a higher short-term Unified Composite Score (49.4/100 HOLD vs. LQDA 25.6/100 SELL), LQDA captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (47.1% vs. -2747.5% operating margin) and revenue trajectory (+314.6% vs. -100.0% YoY).
  • Technical & Structure Timing Caution: ZBIO is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.0); meanwhile LQDA is in a Breakdown options structure phase (RSI 64.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ZBIO vs LQDA
ZBIO NASDAQ
Zenas BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$27.93
-0.29% 1D
Market Cap $1.9B
TTM Revenue $11M
Forward P/E N/M
Beta / 30D Vol 1.16β · 59% Vol
Unified Composite Score
49.4 / 100 HOLD
Tech 44.0 Fund 53.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -5.2%) with fading momentum, RSI 49
RSI-14: 49.0 · SMA20: $27.99 · SMA50: $28.48
LQDA NASDAQ Head-to-Head Winner
Liquidia Corporation Common Stock
Pharmaceutical Preparations
$56.37
-1.81% 1D
Market Cap $5.2B
TTM Revenue $622M
Forward P/E 16.4x
Beta / 30D Vol 0.99β · 77% Vol
Unified Composite Score
25.6 / 100 SELL
Tech 50.0 Fund 36.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 64
RSI-14: 64.4 · SMA20: $46.46 · SMA50: $48.72

6-Pillar Scorecard Institutional Category Breakdown (ZBIO 1 – 5 LQDA)

Columns: Metric · ZBIO · LQDA
1. Valuation Multiples LQDA
Forward P/E N/M 16.4x
Trailing P/E N/M 13.8x
PEG Ratio N/M N/M
EV / Revenue N/M 8.0x
2. Growth & Scale LQDA
Revenue Growth (YoY) -100.0% +314.6%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $11M $622M
Market Cap $1.9B $5.2B
3. Profitability & Quality LQDA
Gross Margin N/A 92.7%
Operating Margin -2747.5% 47.1%
Net Profit Margin 0.0% -15.2%
Return on Equity (ROE) -265.1% 131.8%
4. Balance Sheet & Cash Flow LQDA
Cash Generation (TTM) -$273M $288M
Cash Flow Margin N/A 46.3%
Net Cash / Leverage $177M Net Cash $227M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ZBIO
Options Structure Phase CONSOLIDATION BREAKDOWN
Current IV / %ile 103.9% (13th %ile) 69.3% (10th %ile)
Put/Call OI Skew N/A 0.08x (Call-Skewed)
OBV Trend / Tech Phase ACCUMULATION · Distribution ACCUMULATION · Neutral
6. R&D & Supply-Chain Moat LQDA
OpEx & R&D Intensity N/A 45.6% of Rev ($284M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning High-Margin Pricing Power Moat
Supply-Chain Role Biotechnology Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ZBIO (3) vs LQDA (7)
Institutional Metric ZBIO LQDA Criterion Row Edge
Market Capitalization
Scale
$1.9B $5.2B Larger Scale LQDA
Trailing P/E Ratio
Valuation
N/M 13.8x Lower Multiple LQDA
Forward P/E Ratio
Valuation
N/M 16.4x Lower Multiple LQDA
Revenue Growth (YoY)
Growth
-100.0% +314.6% Higher Growth LQDA
Operating Margin (TTM)
Profitability
-2747.5% 47.1% Higher Margin LQDA
Net Profit Margin
Profitability
0.0% -15.2% Higher Margin ZBIO
Return on Equity (ROE)
Capital Efficiency
-265.1% 131.8% Higher ROE LQDA
52-Week Range Position
Momentum
46% ($14–$45) 48% ($22–$94) Stronger Trend LQDA
Beta / 30D Volatility
Risk Regime
1.16β · 59% Vol 0.99β · 77% Vol Lower Realized Risk ZBIO
Unified Institutional Score
Composite Signal
49.4 / 100 (HOLD) 25.6 / 100 (SELL) Higher Composite ZBIO
Trailing 12M Revenue (USD)
Operating Scale
$11M $622M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 92.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 8.0x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$273M ($177M Net Cash) $288M ($227M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon LQDA +51.66 pp
ZBIO: +12.44% · LQDA: +64.1%
3M Horizon ZBIO +11.69 pp
ZBIO: -12.47% · LQDA: -24.16%
6M Horizon ZBIO +66.22 pp
ZBIO: +65.17% · LQDA: -1.05%
1Y Horizon LQDA +130.92 pp
ZBIO: -21.68% · LQDA: +109.24%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ZBIO Revenue LQDA Revenue ZBIO Op. Margin LQDA Op. Margin Margin Leader
FY2019 N/A $10M N/A -580.1% LQDA
FY2020 N/A $0M N/A -7989.0% LQDA
FY2021 N/A $10M N/A -263.0% LQDA
FY2022 N/A $20M N/A -243.3% LQDA
FY2023 $50M $20M -74.3% -419.6% ZBIO
FY2024 $10M $10M -3277.8% -866.6% LQDA
FY2025 $10M $160M -3830.6% -32.5% LQDA

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ZBIO CONSOLIDATION
58d in phase · OBV ACCUMULATION
Current IV 103.9%
IV Percentile 13th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact ZBIO Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
LQDA BREAKDOWN
81d in phase · OBV ACCUMULATION
Current IV 69.3%
IV Percentile 10th %ile
Put/Call OI Skew 0.08x (Call-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact LQDA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ZBIO Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $1.9B market capitalization and -2747.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
LQDA Moat Profile High-Margin Pricing Power Moat
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $5.2B market capitalization and 47.1% operating margin.
OpEx & R&D Reinvestment 45.6% of Rev ($284M)
90D Engineering Disclosures 0 Published

Investor FAQ ZBIO vs LQDA Key Questions & Quantitative Answers

As of Nov 16, 2026, Liquidia Corporation (LQDA) is the stronger overall head-to-head candidate over Zenas BioPharma, Inc. (ZBIO) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). ZBIO carries a Unified Composite Score of 49.4/100 (HOLD) at $27.93 (N/M Forward P/E, -2747.5% operating margin), whereas LQDA carries 25.6/100 (SELL) at $56.37 (16.4x Forward P/E, 47.1% operating margin). Composite vs. Pillar Nuance: While ZBIO currently prints a higher short-term Unified Composite Score (49.4/100 HOLD vs. LQDA 25.6/100 SELL), LQDA captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (47.1% vs. -2747.5% operating margin) and revenue trajectory (+314.6% vs. -100.0% YoY). Technical & Structure Timing Caution: ZBIO is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.0); meanwhile LQDA is in a Breakdown options structure phase (RSI 64.4). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

LQDA leads the Growth & Scale pillar: ZBIO posts -100.0% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, -2747.5% operating margin), compared with LQDA at +314.6% YoY revenue growth and +0.0% YoY earnings growth on $622M TTM revenue (92.7% gross margin, 47.1% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), ZBIO cumulative revenue shifted -80.0% while LQDA shifted +1500.0%. In operating R&D and SG&A reinvestment, ZBIO deploys N/A (0 90-day corporate R&D disclosures) versus 45.6% of Rev ($284M) (0 disclosures) for LQDA.

LQDA screens cheaper on headline valuation multiples. ZBIO trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas LQDA trades at 16.4x Forward P/E, 13.8x Trailing P/E, N/M PEG, and 8.0x EV/Revenue (46.3% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ZBIO (-265.1% ROE) versus LQDA (131.8% ROE) capital efficiency.

In options market volatility and institutional positioning, ZBIO carries 103.9% implied volatility (13th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.16β · 59% Vol realized risk). By comparison, LQDA carries 69.3% implied volatility (10th %ile, Compressed (<25th %ile)), a 0.08x (Call-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (0.99β · 77% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.